Laura Lea Henness, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 518 Brown Circle Dr, Osawatomie, KS 66064 Phone: 913-731-2751 |
News Archive
The family of bacteria that causes tuberculosis (TB) and leprosy are notoriously sturdy. And although the diseases they cause have been held in check for the past 50 years by antibiotics, some strains are becoming increasingly resistant to existing therapy.
Maxim Pharmaceuticals has announced that based upon the negative outcome of it's confirmatory Phase 3 clinical trial (M0104) studying Ceplene(TM) (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) in advanced malignant melanoma patients with liver metastases, it plans to close the treatment protocol approved by the FDA earlier this year.
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the commercial launch of the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, following FDA 510(k) clearance in June and a limited pre-launch in July. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical, LP (Rex Medical), as announced in March 2008.
Minneapolis-St. Paul Business Journal: UnitedHealth Group's technology consulting subsidiary Ingenix, of Eden Prairie, Minn., has purchased Massachusetts tech firm Picis, a maker of emergency room and intensive care software. "Both companies are deeply involved in the area where health care and information technology meet. Ingenix, which had revenue of $1.8 billion last year, provides consulting and outsourcing to almost 6,000 hospitals.
› Verified 1 days ago